Caribou Biosciences reported second quarter 2026 financial results and provided a business update on August 13, 2026. The company posted a GAAP net loss of $24.3 million, or $0.24 per share, compared to a $54.1 million loss in the prior year period. Revenue from licensing agreements decreased to $1.5 million from $2.7 million, while R&D and G&A expenses fell to $18.9 million and $7.9 million respectively due to workforce reductions and strategic prioritization announced in April 2025. Cash and marketable securities stood at $113.8 million as of June 30, 2026, sufficient to fund operations through the end of 2027. Clinically, data presented at EHA 2026 reinforced vispa-cel's safety and efficacy in second-line large B cell lymphoma and demonstrated deep responses for CB-011 in multiple myeloma.

Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 clinical trial for vispa-cel in r/r B-NHL, showing an 82% overall response rate and 67% complete response rate in a pivotal optimized subgroup. The company also reported dose escalation data from its CaMMouflage phase 1 trial for CB-011 in r/r MM, which demonstrated a 92% overall response rate and 83% complete response rate in a BCMA-naïve cohort. Caribou Biosciences is a biotechnology company developing allogeneic CAR-T cell therapies for cancer treatment.